Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Table 1 Baseline characteristics of the study population, n (%)

Variable	TMF group 25 mg (n = 106)	TAF group 25 mg (n = 109)	P value
Male	71 (66.98)	74 (67.89)	0.887
Age (yr)	40.96 ± 11.25	40.19 ± 9.84	0.707
Routine blood test
WBC (× 109/L)	5.59 ± 1.64	5.59 ± 1.49	0.792
PLT (× 109/L)	193.97 ± 67.44	181.98 ± 68.63	0.218
Liver function
Albumin (g/L)	45.57 ± 3.64	45.46 ± 3.59	0.746
Globulin (g/L)	29.32 ± 3.66	29.49 ± 3.70	0.617
TBIL (μmol/L)	4.55 (3.70, 5.90)	4.75 (2.20, 18.78)	0.070
DBIL (μmol/L)	2.50 (1.50, 3.90)	5.85 (4.10, 8.33)	0.152
ALT (U/L)	28.30 (20.10, 46.70)	32.40 (22.35, 49.60)	0.203
AST (U/L)	30.50 (24.90, 39.00)	30.00 (24.83, 40.80)	0.740
Kidney function
BUN (mmol/L)	4.75 (3.99, 6.11)	4.88 (4.22, 5.70)	0.856
Creatinine (μmol/L)	79.50 (66.05, 91.00)	83.30 (73.00, 93.90)	0.177
eGFR (ml/min/1.73 m2)	90.58 (79.84, 103.80)	97.19 (87.335, 106.38)	0.180
Viral load
HBV DNA < 10 IU/mL	34 (32.08)	44 (40.37)	0.206
HBeAg positive	39 (36.79)	46 (42.20)	0.417
Blood lipid
Triglycerides (mmol/L)	1.57 ± 0.82	1.65 ± 1.19	0.719
Total cholesterol (mg/dl)	4.83 ± 1.09	4.30 ± 1.54	0.173
HDL	1.18 ± 0.21	1.10 ± 0.14	0.341
LDL	3.19 ± 0.91	3.20 ± 0.94	0.877
Phosphorus (mmol/L)	1.64 ± 3.84	1.05 ± 0.44	0.958
AFP (ng/mL)	5.19 ± 8.90	5.24 ± 7.89	0.167
LSM (Kpa)	10.17 ± 4.41	10.94 ± 3.37	0.108
FIB-4 score	1.15 (0.75, 1.77)	1.27 (0.87, 2.03)	0.552
Underlying diseases
Diabetes	5 (4.72)	6 (5.50)	0.793
Cirrhosis	23 (21.70)	19 (17.43)	0.430
Decompensated cirrhosis	4 (3.77)	4 (3.67)	0.968
Hepatocellular carcinoma	2 (1.89)	3 (2.75)	0.674
NAFLD	26 (24.53)	28 (25.69)	0.845
Treatment naïve	63 (59.43)	61 (55.96)	0.607

Data are frequency (%), median M (P25, P75), or mean ± SD deviation. TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; WBCs: White blood cells; PLTs: Platelets; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; BUN: Blood urea nitrogen; eGFR: Estimated glomerular filtration rate; P: Phosphorus; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; AFP: Alpha fetoprotein; LSM: Liver stiffness measurement; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; NAFLD: Nonalcoholic fatty liver disease; FIB-4: Fibrosis-4.

Table 2 Comparison of changes in serum creatinine and estimated glomerular filtration rate between the tenofovir amibufenamide and tenofovir alafenamide groups.

	TMF group (n = 106)	TAF group (n = 109)	P value
Creatinine (μmol/L)
Before treatment	79.50 (66.05, 91.00)	83.30 (73.00, 93.90)	0.856
After 48 wk	72.00 (63.00, 83.00)	78.10 (61.00, 90.70)	0.194
Reduction	4.00 (-19.65, 19.50)	3.37 (-7.96, 26.13)	0.728
P (baseline vs. 48 wk)	0.053	0.105
eGFR (mL/min/1.73 m2)
Before treatment	90.58 (79.84, 103.80)	97.19 (87.35, 106.38)	0.180
After 48 wk	106.37 (94.58, 113.15)	105.17 (88.15,129.56)	0.617
Reduction	-2.22 (-9.72, 16.75)	-4.17 (-227.89, 7.67)	0.093
P (baseline vs. 48 wk)	0.301	0.108

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; eGFR: Estimated glomerular filtration rate.

Table 3 Changes in blood lipid profiles between the tenofovir amibufenamide and tenofovir alafenamide groups

	TMF group (n = 106)	TAF group (n = 109)	P value
Triglycerides (mmol/L)
Before treatment	1.57 ± 0.82	1.65 ± 1.19	0.719
After 48 wk	2.16 ± 1.34	1.81 ± 0.87	0.931
Reduction	-0.64 ± 1.02	0.19 ± 0.31	0.103
P (baseline vs. 48 wk)	0.099	0.359
Total cholesterol (mg/dl)
Before treatment	4.83 ± 1.09	4.30 ± 1.54	0.173
After 48 wk	4.82 ± 1.52	5.20 ± 0.99	0.581
Reduction	-0.23 ± 0.95	-1.02 ± 1.18	0.182
P (baseline vs. 48 wk)	0.822	0.045
HDL (mmol/L)
Before treatment	1.18 ± 0.21	1.10 ± 0.14	0.341
After 48 wk	1.43 ± 0.74	1.23 ± 0.31	0.977
Reduction	-0.23 ± 0.71	-0.09 ± 0.16	0.672
P (baseline vs. 48 wk)	0.430	0.225
LDL (mmol/L)
Before treatment	3.19 ± 0.91	3.20 ± 0.94	0.877
After 48 wk	3.15 ± 1.18	3.40 ± 0.71	0.428
Reduction	0.10 ± 0.94	-0.04 ± 0.9	0.791
P (baseline vs. 48 wk)	0.807	0.332

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.